ArticleInternational journal of laboratory hematology2026
Hemoscreen Point-of-Care Analyzer Compared With Sysmex XN-1000 for Complete Blood Count in Pediatric Inpatients Aged 2 Months to 17 Years.
Article in International journal of laboratory hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionHemoScreen is an image-based point-of-care (POC) hematology analyzer that performs complete blood counts (CBC) from small blood volumes with minimal handling. These features are particularly relevant in pediatrics; however, comparative evidence with central laboratory analyzers in children remains limited.
methodsWe compared HemoScreen POC with Sysmex XN-1000 analyzer in 141 venous K
resultsCorrelations were strong to excellent, with no significant deviation from linearity. Mean biases were below the minimum acceptable limits for most parameters. Using the Passing-Bablok regression as the reference line, the proportion of measurements exceeding limits was below 10% for WBC, RBC, PLT, and most other CBC indices in at least one of the tested TEa thresholds. Diagnostic agreement was excellent for leukopenia, leukocytosis, thrombocytopenia, anemia, and elevated HGB; good-excellent for thrombocytosis and macrocytosis; and good for microcytosis.
conclusionIn venous samples from pediatric inpatients (2 months-17 years), HemoScreen showed high analytical and diagnostic agreement with the Sysmex XN-1000, supporting its use in children's hospitals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.